Cargando…

Lymphatic leakage after pelvic lymphadenectomy for cervical cancer: a retrospective case-control study

BACKGROUND: The study aims to evaluate the clinical features and management of postoperative lymphatic leakage (PLL) in patients with cervical cancer who received pelvic lymphadenectomy. METHODS: This retrospective study screened consecutive patients with cervical cancer (stage Ia2-IIb). RESULTS: Am...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Li, Lin, Liang, Li, Ling, Xie, Zuolian, He, Haixin, Lin, Cuibo, Chen, Jian, Lin, An
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603468/
https://www.ncbi.nlm.nih.gov/pubmed/34794409
http://dx.doi.org/10.1186/s12885-021-08984-1
_version_ 1784601770472767488
author Chen, Li
Lin, Liang
Li, Ling
Xie, Zuolian
He, Haixin
Lin, Cuibo
Chen, Jian
Lin, An
author_facet Chen, Li
Lin, Liang
Li, Ling
Xie, Zuolian
He, Haixin
Lin, Cuibo
Chen, Jian
Lin, An
author_sort Chen, Li
collection PubMed
description BACKGROUND: The study aims to evaluate the clinical features and management of postoperative lymphatic leakage (PLL) in patients with cervical cancer who received pelvic lymphadenectomy. METHODS: This retrospective study screened consecutive patients with cervical cancer (stage Ia2-IIb). RESULTS: Among 3427 cases screened, 63 patients (1.8%) were diagnosed with PLL, which manifested as persistent abdominal drainage (42/63, 66.7%), chylous ascites (12/63, 19.0%) or vaginal drainage (9/63, 14.3%). Median time from surgery to onset of PLL was 6 days (range, 4–21 days). All cases resolved in a median 10 days (range, 3–56 days) after conservative treatment; although one case experienced recurrence of vaginal drainage after 26 days, this also resolved after conservative therapy. Multivariate analysis showed that two cycles of neoadjuvant chemotherapy (odds ratio [OR], 3.283; 95% confidence interval [95%CI], 1.289–8.360; P = 0.013), a decrease in hemoglobin level of ≥20 and < 30 g/L (OR, 6.175; 95%CI, 1.033–10.919; P = 0.046) or ≥ 30 g/L (OR, 8.467; 95%CI, 1.248–17.426; P = 0.029), and postoperative albumin level ≥ 30 and < 35 g/L (OR, 2.552; 95%CI, 1.112–5.857; P = 0.027) or < 30 g/L (OR, 5.517; 95%CI, 2.047–18.148; P = 0.012) were associated with PLL. CONCLUSION: Neoadjuvant chemotherapy, postoperative anemia and postoperative hypoproteinemia are risk factors for PLL.
format Online
Article
Text
id pubmed-8603468
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-86034682021-11-19 Lymphatic leakage after pelvic lymphadenectomy for cervical cancer: a retrospective case-control study Chen, Li Lin, Liang Li, Ling Xie, Zuolian He, Haixin Lin, Cuibo Chen, Jian Lin, An BMC Cancer Research BACKGROUND: The study aims to evaluate the clinical features and management of postoperative lymphatic leakage (PLL) in patients with cervical cancer who received pelvic lymphadenectomy. METHODS: This retrospective study screened consecutive patients with cervical cancer (stage Ia2-IIb). RESULTS: Among 3427 cases screened, 63 patients (1.8%) were diagnosed with PLL, which manifested as persistent abdominal drainage (42/63, 66.7%), chylous ascites (12/63, 19.0%) or vaginal drainage (9/63, 14.3%). Median time from surgery to onset of PLL was 6 days (range, 4–21 days). All cases resolved in a median 10 days (range, 3–56 days) after conservative treatment; although one case experienced recurrence of vaginal drainage after 26 days, this also resolved after conservative therapy. Multivariate analysis showed that two cycles of neoadjuvant chemotherapy (odds ratio [OR], 3.283; 95% confidence interval [95%CI], 1.289–8.360; P = 0.013), a decrease in hemoglobin level of ≥20 and < 30 g/L (OR, 6.175; 95%CI, 1.033–10.919; P = 0.046) or ≥ 30 g/L (OR, 8.467; 95%CI, 1.248–17.426; P = 0.029), and postoperative albumin level ≥ 30 and < 35 g/L (OR, 2.552; 95%CI, 1.112–5.857; P = 0.027) or < 30 g/L (OR, 5.517; 95%CI, 2.047–18.148; P = 0.012) were associated with PLL. CONCLUSION: Neoadjuvant chemotherapy, postoperative anemia and postoperative hypoproteinemia are risk factors for PLL. BioMed Central 2021-11-18 /pmc/articles/PMC8603468/ /pubmed/34794409 http://dx.doi.org/10.1186/s12885-021-08984-1 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Chen, Li
Lin, Liang
Li, Ling
Xie, Zuolian
He, Haixin
Lin, Cuibo
Chen, Jian
Lin, An
Lymphatic leakage after pelvic lymphadenectomy for cervical cancer: a retrospective case-control study
title Lymphatic leakage after pelvic lymphadenectomy for cervical cancer: a retrospective case-control study
title_full Lymphatic leakage after pelvic lymphadenectomy for cervical cancer: a retrospective case-control study
title_fullStr Lymphatic leakage after pelvic lymphadenectomy for cervical cancer: a retrospective case-control study
title_full_unstemmed Lymphatic leakage after pelvic lymphadenectomy for cervical cancer: a retrospective case-control study
title_short Lymphatic leakage after pelvic lymphadenectomy for cervical cancer: a retrospective case-control study
title_sort lymphatic leakage after pelvic lymphadenectomy for cervical cancer: a retrospective case-control study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8603468/
https://www.ncbi.nlm.nih.gov/pubmed/34794409
http://dx.doi.org/10.1186/s12885-021-08984-1
work_keys_str_mv AT chenli lymphaticleakageafterpelviclymphadenectomyforcervicalcanceraretrospectivecasecontrolstudy
AT linliang lymphaticleakageafterpelviclymphadenectomyforcervicalcanceraretrospectivecasecontrolstudy
AT liling lymphaticleakageafterpelviclymphadenectomyforcervicalcanceraretrospectivecasecontrolstudy
AT xiezuolian lymphaticleakageafterpelviclymphadenectomyforcervicalcanceraretrospectivecasecontrolstudy
AT hehaixin lymphaticleakageafterpelviclymphadenectomyforcervicalcanceraretrospectivecasecontrolstudy
AT lincuibo lymphaticleakageafterpelviclymphadenectomyforcervicalcanceraretrospectivecasecontrolstudy
AT chenjian lymphaticleakageafterpelviclymphadenectomyforcervicalcanceraretrospectivecasecontrolstudy
AT linan lymphaticleakageafterpelviclymphadenectomyforcervicalcanceraretrospectivecasecontrolstudy